MARKET

BLPH

BLPH

Bellerophon
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.05
-0.02
-0.28%
Opening 12:28 02/24 EST
OPEN
7.11
PREV CLOSE
7.07
HIGH
7.34
LOW
6.85
VOLUME
60.81K
TURNOVER
--
52 WEEK HIGH
26.00
52 WEEK LOW
3.186
MARKET CAP
66.96M
P/E (TTM)
-2.1288
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
[2020-2027] Inhaled Nitric Oxide Market to Garner $1.18 Billion, At CAGR of 8.1%: AMR
GlobeNewswire · 02/17 14:30
Global Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 Healthcare Sector Analysis By Covid-19 Impact On, Size, Trends, Growth, Share, Business, Key Players, Merger, Statistics, Competitive Landscape, And Regional Forecast To 2028
Feb 16, 2021 (The Expresswire) -- Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 Healthcare Sector Global Analysis By Covid-19 Impact On, Size,...
The Express Wire · 02/16 05:20
Bellerophon (BLPH) Gets a Buy Rating from Maxim Group
In a report issued on March 26, Jason McCarthy from Maxim Group maintained a Buy rating on Bellerophon (BLPH), with a price target of $30.00. The
SmarterAnalyst · 02/09 09:08
Clinical Trials Market Size Estimation, Growth Insights and Forecast 2021 to 2030
Market Insight Reports · 02/04 07:08
Reconstruction Mesh Market | 2021 COVID-19 Impact Forecast By Size, Growth Rate, Trends, Share, Business Insights, And Global Healthcare Sector Outlook To 2026
Feb 02, 2021 (The Expresswire) -- Reconstruction Mesh Market | 2021 Healthcare Industry Post COVID-19 Analysis By Size, Business Growth, Share, New Trends,...
The Express Wire · 02/02 05:06
Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 COVID-19 Impact Forecast By Size, Growth Rate, Trends, Share, Business Insights, And Global Healthcare Sector Outlook To 2026
Feb 01, 2021 (The Expresswire) -- Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 Healthcare Industry Post COVID-19 Analysis By Size, Business...
The Express Wire · 02/02 04:53
Global Nitric Oxide Therapy System Market 2020 Industry Overview, Competition by Manufacturers, Production Capacity by Region, Forecast by 2025
Jan 20, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has newly published research study entitled Global Nitric Oxide Therapy System Market 2020...
CDN Newswire · 01/21 02:08
Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 Healthcare Industry COVID-19 Impact Forecast By Size, Growth, Share Estimation, Business, And Global Trends Analysis To 2026
Jan 18, 2021 (The Expresswire) -- Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 COVID-19 Impact On Healthcare Industry Size, Growth Rate,...
The Express Wire · 01/18 07:07
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLPH. Analyze the recent business situations of Bellerophon through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLPH stock price target is 23.67 with a high estimate of 30.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 65
Institutional Holdings: 6.98M
% Owned: 73.50%
Shares Outstanding: 9.50M
TypeInstitutionsShares
Increased
12
209.64K
New
5
-39.63K
Decreased
12
99.83K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.71%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Director
Jonathan Peacock
Chief Executive Officer/Chief Financial Officer/Director
Fabian Tenenbaum
Chief Financial Officer/Secretary
Assaf Korner
Vice President - Operations
Parag Shah
Vice President
Martin Dekker
Vice President - Administration
Amy Edmonds
Other
Wassim Fares
Other
Peter Fernandes
Director
Ted Wang
Independent Director
Naseem Amin
Independent Director
Matthew Bennett
Independent Director
Scott Bruder
Independent Director
Mary Cloyd
Independent Director
Andre Moura
Independent Director
Crispin Teufel
Independent Director
Theodore Wang
  • Dividends
  • Splits
  • Insider Activity
No Data
About BLPH
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. The Company's INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. INOpulse is designed to be compatible with many long-term oxygen therapy (LTOT) systems via nasal cannula delivery.

Webull offers kinds of Bellerophon Therapeutics Inc stock information, including NASDAQ:BLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLPH stock methods without spending real money on the virtual paper trading platform.